Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchoscopy | 8 | 2023 | 225 | 0.690 |
Why?
|
| Chylothorax | 3 | 2019 | 20 | 0.320 |
Why?
|
| Lymphography | 2 | 2018 | 13 | 0.280 |
Why?
|
| Thoracoscopy | 2 | 2019 | 58 | 0.270 |
Why?
|
| Stents | 2 | 2020 | 526 | 0.240 |
Why?
|
| Airway Management | 1 | 2024 | 64 | 0.210 |
Why?
|
| Pulmonary Medicine | 1 | 2024 | 82 | 0.210 |
Why?
|
| Robotics | 1 | 2004 | 87 | 0.190 |
Why?
|
| Surgical Procedures, Operative | 1 | 2004 | 266 | 0.170 |
Why?
|
| Fellowships and Scholarships | 1 | 2024 | 310 | 0.170 |
Why?
|
| Dyspnea | 1 | 2022 | 254 | 0.160 |
Why?
|
| Academic Medical Centers | 3 | 2017 | 513 | 0.160 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 2533 | 0.160 |
Why?
|
| Constriction, Pathologic | 1 | 2020 | 238 | 0.160 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 320 | 0.150 |
Why?
|
| Biopsy | 3 | 2017 | 1072 | 0.150 |
Why?
|
| Thoracentesis | 1 | 2019 | 6 | 0.150 |
Why?
|
| Respiratory Tract Diseases | 1 | 2020 | 181 | 0.150 |
Why?
|
| Chyle | 1 | 2018 | 4 | 0.150 |
Why?
|
| Critical Care | 1 | 2024 | 653 | 0.150 |
Why?
|
| Airway Obstruction | 2 | 2020 | 164 | 0.150 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2018 | 26 | 0.140 |
Why?
|
| Pericardial Effusion | 1 | 2018 | 21 | 0.140 |
Why?
|
| Pleural Effusion | 1 | 2019 | 57 | 0.140 |
Why?
|
| Lymphatic Abnormalities | 1 | 2017 | 20 | 0.130 |
Why?
|
| Lung Transplantation | 1 | 2020 | 313 | 0.130 |
Why?
|
| Pneumothorax | 1 | 2017 | 46 | 0.130 |
Why?
|
| Cryosurgery | 1 | 2017 | 45 | 0.130 |
Why?
|
| Bronchial Neoplasms | 1 | 2016 | 16 | 0.130 |
Why?
|
| Pericarditis | 1 | 2016 | 11 | 0.130 |
Why?
|
| Cryotherapy | 1 | 2016 | 20 | 0.130 |
Why?
|
| Empyema, Pleural | 1 | 2016 | 12 | 0.120 |
Why?
|
| Embolization, Therapeutic | 1 | 2018 | 234 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1111 | 0.100 |
Why?
|
| Hemorrhage | 1 | 2017 | 747 | 0.090 |
Why?
|
| Image-Guided Biopsy | 2 | 2023 | 39 | 0.090 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2017 | 651 | 0.080 |
Why?
|
| Fluoroscopy | 2 | 2023 | 166 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 1939 | 0.060 |
Why?
|
| Phosphotyrosine | 1 | 2006 | 40 | 0.060 |
Why?
|
| Growth Inhibitors | 1 | 2006 | 45 | 0.060 |
Why?
|
| Humans | 17 | 2024 | 138972 | 0.060 |
Why?
|
| Antigens, Differentiation | 1 | 2005 | 82 | 0.060 |
Why?
|
| Antigens, Surface | 1 | 2005 | 154 | 0.060 |
Why?
|
| Receptors, Immunologic | 1 | 2006 | 213 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 2006 | 1148 | 0.060 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2005 | 193 | 0.060 |
Why?
|
| Lung | 1 | 2017 | 4103 | 0.050 |
Why?
|
| Neurosurgery | 1 | 2004 | 41 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2023 | 15901 | 0.050 |
Why?
|
| Urologic Surgical Procedures | 1 | 2004 | 114 | 0.050 |
Why?
|
| Pelvic Pain | 1 | 2002 | 36 | 0.050 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2022 | 56 | 0.050 |
Why?
|
| Endosonography | 1 | 2023 | 152 | 0.050 |
Why?
|
| Forecasting | 1 | 2004 | 384 | 0.050 |
Why?
|
| Male | 8 | 2024 | 68250 | 0.050 |
Why?
|
| Anesthesiology | 1 | 2024 | 159 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2020 | 10921 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2002 | 142 | 0.040 |
Why?
|
| Orthopedic Procedures | 1 | 2004 | 229 | 0.040 |
Why?
|
| Sports Medicine | 1 | 2002 | 113 | 0.040 |
Why?
|
| Equipment Failure | 1 | 2020 | 110 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2022 | 492 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2006 | 1097 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2004 | 980 | 0.040 |
Why?
|
| Tuberculosis, Pleural | 1 | 2019 | 7 | 0.040 |
Why?
|
| Pleura | 1 | 2019 | 24 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 543 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2022 | 1370 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2020 | 561 | 0.040 |
Why?
|
| Safety | 1 | 2020 | 348 | 0.040 |
Why?
|
| Female | 6 | 2024 | 74016 | 0.040 |
Why?
|
| Thoracic Duct | 1 | 2017 | 7 | 0.030 |
Why?
|
| Rosaniline Dyes | 1 | 2017 | 14 | 0.030 |
Why?
|
| Fungi | 1 | 2019 | 150 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2004 | 576 | 0.030 |
Why?
|
| Bronchi | 1 | 2019 | 269 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2005 | 1985 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2017 | 131 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2017 | 69 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2019 | 554 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2024 | 1149 | 0.030 |
Why?
|
| Biofilms | 1 | 2019 | 266 | 0.030 |
Why?
|
| Sputum | 1 | 2018 | 305 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 172 | 0.030 |
Why?
|
| CD28 Antigens | 2 | 2006 | 56 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 609 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2006 | 5092 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 1085 | 0.030 |
Why?
|
| Hypoxia | 1 | 2022 | 1148 | 0.030 |
Why?
|
| Contrast Media | 1 | 2017 | 463 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2004 | 3466 | 0.030 |
Why?
|
| Middle Aged | 3 | 2020 | 33782 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2020 | 3574 | 0.020 |
Why?
|
| Bacteria | 1 | 2019 | 868 | 0.020 |
Why?
|
| Phenotype | 1 | 2020 | 3143 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 5884 | 0.020 |
Why?
|
| Microbiota | 1 | 2019 | 760 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 1522 | 0.020 |
Why?
|
| Aged | 2 | 2020 | 24172 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2006 | 8 | 0.020 |
Why?
|
| Vanadates | 1 | 2006 | 17 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2006 | 22 | 0.020 |
Why?
|
| Adult | 2 | 2020 | 38393 | 0.020 |
Why?
|
| United States | 1 | 2004 | 15074 | 0.020 |
Why?
|
| Risk Factors | 1 | 2020 | 10385 | 0.020 |
Why?
|
| Okadaic Acid | 1 | 2005 | 15 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2005 | 25 | 0.020 |
Why?
|
| Dimerization | 1 | 2006 | 198 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2006 | 225 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2005 | 67 | 0.010 |
Why?
|
| Phosphatidylinositols | 1 | 2005 | 59 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2005 | 104 | 0.010 |
Why?
|
| CTLA-4 Antigen | 1 | 2005 | 99 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2006 | 167 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2006 | 451 | 0.010 |
Why?
|
| Protein Transport | 1 | 2006 | 443 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2005 | 819 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2005 | 1090 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 368 | 0.010 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2005 | 254 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 663 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 464 | 0.010 |
Why?
|
| Osteitis | 1 | 2002 | 4 | 0.010 |
Why?
|
| Psoas Muscles | 1 | 2002 | 14 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2005 | 537 | 0.010 |
Why?
|
| Hip | 1 | 2002 | 57 | 0.010 |
Why?
|
| Tendinopathy | 1 | 2002 | 28 | 0.010 |
Why?
|
| Endometriosis | 1 | 2002 | 53 | 0.010 |
Why?
|
| Pelvis | 1 | 2002 | 113 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2005 | 1767 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 2480 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2002 | 1804 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2005 | 2591 | 0.010 |
Why?
|
| Mutation | 1 | 2006 | 3984 | 0.010 |
Why?
|
| Mice | 1 | 2006 | 17828 | 0.000 |
Why?
|
| Animals | 1 | 2006 | 37243 | 0.000 |
Why?
|